Regeneron Will Move Two Factor XI Agents Into Phase III

With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.

Regeneron reports positive Phase II data for two factor XI anticoagulants • Source: Shutterstock

In a battle with Bristol Myers Squibb/Johnson & Johnson, Bayer and privately held Anthos to bring the first factor XI anticoagulant product to market, Regeneron reported on 19 December that its pair of factor XI-targeted antibodies succeeded in Phase II studies and are expected to advance into Phase III in 2025.

Key Takeaways
  • Regeneron plans to advance its two factor XI anticoagulant candidates into Phase III after reporting positive data from two Phase II trials.

The Tarrytown, NY-based firm is developing REGN7508, which targets factor XI’s catalytic domain, and REGN9933, which acts on the A2...

More from Strategy

More from Therapy Areas

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.